CLINICAL_TRIALS
trial_result
· 2015-02-05
Clinical Trial Update: Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder [Phase 2]
Summary
Phase 2 trial results evaluate the efficacy of Lu AA21004 (vortioxetine) on cognitive dysfunction in patients with major depressive disorder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED | Results posted: 2015-02-05